TABLE 2.
Clinical course of COVID-19 patients with acute respiratory distress treated with ramatroban.
| Patient initials, gender, age (years), and comorbidity | Ramatroban (Baynas®) 75 mg tab | Clinical course; blood oxygen saturation by pulse oximetry (SpO2) | ||
|---|---|---|---|---|
| Time “0” ramatroban started | Time to partial relief of dyspnea; and the first SpO2 recorded on room air after initiating ramatroban treatment | Day “5” after taking 10 tablets of ramatroban b | ||
| S.D.; female, 87 years. Hypertension; Stage 4 CKD; CAD, MI, and cardiac arrest 4 years ago | 37.5 mg (½ tab) twice daily | Dyspnea ++ SpO2 : 82% | 24–36 h; SpO2 > 90%, 36 h after first dose a | No dyspnea SpO2 ≥ 95% |
| A.K., male, 33 years. Hypertension, psoriasis, and recurrent URTI | 75 mg twice daily | Dyspnea +++ SpO2 : 73% | 1–2 h; SpO2 90%, 9 h after first dose b | No dyspnea SpO2 96% |
| S.B., female, 22 years | 75 mg twice daily | Dyspnea ++ SpO2 : 85% | 4–6 h; SpO2 89%, 6–8 h after first dose | No dyspnea SpO2 94% |
| B.C., male, 70 years. Diabetes mellitus | 75 mg twice daily | Dyspnea ++ SpO2 : 80% | 2–3 h; SpO2 85%, 2–3 h after first dose | No dyspnea SpO2 96% |
a
SpO2 on room air was not checked at earlier time points.
b
For patients 2, 3, and 4, ramatroban could be administered only for a total of 5 days due to limited supplies.